NextPlat Corp (NXPL) Fair Value & Analysis
Technology · US · Market cap $15.7M
Fair value as of: Jun 25, 2026
Analysis
NextPlat Corp (NXPL) currently trades at $6.48, while our model-based Fair Value estimate is $5.17 — implying the stock looks roughly 20.2% overvalued today. We read business quality at 95/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, Asia and Pacific, and Africa. It operates through two segments, e-Commerce Operations and Healthcare Operations. The company operates full-service retail and specialty services pharmacies that provide prescription pharmaceuticals, third-party administration, risk and data management, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, medication adherence packaging, contracted pharmacy services, health practice risk management, disease testing, contracted pharmacy, and vaccinations services, as well as supplies prescription medications. It also operates e-commerce websites, as well as third-party e-commerce storefronts that provide mobile satellite services solutions for satellite-enabled voice, data, personnel and asset tracking, machine-to-machine, and internet of things connectivity services; voice, data communications, int…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is NextPlat Corp (NXPL) undervalued?
What is the fair value of NXPL?
What is the quality score of NXPL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.